Ipca Laboratories Ltd logo

Ipca Laboratories Ltd

IPCALAB NSE

Key Fundamentals

Volatility
Moderate
P/E Ratio
39.94
EBITDA
₹2,153 Cr
Return on Equity
12.51%
Debt to Equity
0.1
EPS
₹23.14
52W High
₹1,944.9
52W Low
₹1,251.6

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Ipca Laboratories Ltd insights

48 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

1
  • Company has reduced debt.

Weaknesses

2
  • Stock is trading at 5.56 times its book value
  • Company has a low return on equity of 12.9% over last 3 years.

Growth Rate

Revenue Growth
8.73% ↗
Net Income Growth
51.29% ↗
Cash Flow Change
-13.57% ↘
ROE
33.23% ↗
ROCE
26.29% ↗
EBITDA Margin (Avg.)
8.84% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 8d ago
AI opinion · based on fundamentals
Risk medium

Ipca Laboratories trades at a market cap of ~₹42,952 crore with a PE of 36x and P/B of 5.29x. Consolidated revenue grew 16% YoY to ₹8,940 crore in FY25 with net profit rising 35% to ₹738 crore, while EBITDA margin expanded from 16.7% to 18.9%. The company has reduced debt materially, though ROE remains moderate at around 13-16% over recent years.

Bull Case 8
  • Consolidated net profit grew 35% YoY in FY25 to ₹738 crore from ₹547 crore, demonstrating strong earnings recovery
  • Consolidated revenue grew 16% YoY to ₹8,940 crore in FY25, with 3-year compounded sales CAGR of 16%
  • EBITDA margin expanded 222 bps from 16.72% in FY24 to 18.94% in FY25, reflecting improving operational efficiency
  • Company has actively reduced debt, lowering interest cost to just 0.59% of revenue from operations, versus 1.96% two years prior
  • Raw material cost as a percentage of revenue declined to 25.31% from 35.58% two years ago, supporting margin expansion
  • Diversified revenue mix with ~57% domestic and ~43% export exposure provides geographic risk mitigation
  • Stock has delivered 25% CAGR over 3 years and 21% CAGR over 10 years, reflecting consistent long-term wealth creation track record
  • TTM profit growth of 39% significantly outpaces TTM revenue growth of 8%, indicating strong operating leverage kicking in
Bear Case 8
  • PE ratio of 36x is elevated relative to the pharma sector average, leaving limited margin of safety if growth slows
  • Stock trades at 5.29x book value (screener flags 5.56x), expensive for a business with 3-year average ROE of only 12.9%
  • 5-year compounded profit CAGR is just 1%, reflecting significant earnings volatility between FY22 peak and FY23-24 trough
  • ROE averaged only 13% over 3 and 5 years, below what the valuation premium typically demands in Indian pharma
  • TTM revenue growth slowed to 8% versus the 3-year CAGR of 16%, suggesting potential deceleration in topline momentum
  • Dividend yield of just 0.35% offers negligible income return to shareholders at current valuations
  • Q4 FY24 standalone profit had declined 22% YoY, indicating quarter-to-quarter earnings can be lumpy and unpredictable
  • R&D spending at ~3.3% of revenue is modest for a company looking to build a complex generics pipeline for regulated markets

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Positives 2
  • FY26 net profit surges 74% Jul 14

    Standalone net profit jumped 74.03% YoY to ₹1,132.52 Crores on total income of ₹7,431.39 Crores (up 10.11% YoY). Consolidated income rose 8.73% to ₹9,820.78 Crores.

  • Emissions intensity down 13.5% Jul 14

    BRSR filing shows 13.5% reduction in Scope 1 and 2 emissions intensity and 50.8% diversion of hazardous waste from landfills in FY 2025-26.

Neutral 3
  • Q1FY27 earnings call Aug 14 Aug 6

    Ipca Laboratories will announce Q1FY27 financial results on August 13, 2026, followed by an earnings conference call on August 14 (15:30–16:30 IST).

  • 76th AGM scheduled Aug 13 Jul 15

    76th AGM set for August 13, 2026 via video conferencing with August 7 as record date for dividend entitlement.

  • ₹49 Cr block trade on NSE Jul 16

    Approximately 2,61,941 shares traded in a block deal at ₹1,875 per share, totalling ₹49.11 crore, likely an institutional transaction.

TL;DR: Ipca Laboratories is in strong financial shape with FY26 net profit surging 74% and double-digit revenue growth on a standalone basis. ESG metrics are improving with meaningful emissions reductions. No visible headwinds emerged in recent news flow. With Q1FY27 results due August 13, investors will watch whether the margin expansion trajectory sustains into the new fiscal year.

Quarterly Results

  Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales
1,512
1,585
2,034
2,053
2,033
2,093
2,355
2,245
2,247
2,309
2,556
2,392
2,388
Expenses
1,331
1,278
1,673
1,722
1,711
1,700
1,913
1,782
1,818
1,892
2,012
1,859
1,905
Operating Profit
181
308
361
331
322
393
441
463
429
416
545
533
484
OPM %
12%
19%
18%
16%
16%
19%
19%
21%
19%
18%
21%
22%
20%
Other Income
36
45
-1
91
-118
21
26
20
-179
33
-30
38
48
Interest
18
31
44
33
29
24
23
17
22
19
20
18
20
Depreciation
70
69
90
100
98
99
100
98
100
100
103
108
107
PBT
129
252
225
289
77
290
345
368
128
331
392
446
404
Tax %
37%
34%
39%
23%
96%
31%
29%
25%
49%
29%
28%
18%
24%
Net Profit
78
164
136
221
1
199
246
276
64
233
281
364
307
EPS in Rs
3.02
6.42
5.72
7.09
2.35
7.58
9.05
9.78
2.67
9.19
11.14
12.86
11.79
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Sales
3,144
2,867
3,156
3,258
3,746
4,619
5,395
5,797
6,204
7,662
8,897
9,599
Expenses
2,604
2,573
2,705
2,803
3,051
3,715
3,843
4,472
5,272
6,338
7,166
7,609
Operating Profit
541
294
451
455
695
904
1,552
1,325
932
1,324
1,731
1,990
OPM %
17%
10%
14%
14%
19%
20%
29%
23%
15%
17%
19%
21%
Other Income
32
21
11
41
56
65
59
54
123
17
-114
80
Interest
32
35
27
28
22
20
12
11
48
141
88
79
Depreciation
180
163
173
178
182
210
209
232
262
357
398
418
PBT
361
117
262
291
546
739
1,389
1,136
745
843
1,131
1,573
Tax %
28%
18%
26%
18%
19%
18%
17%
20%
34%
37%
30%
24%
Net Profit
254
93
195
239
442
604
1,141
890
479
523
785
1,184
EPS in Rs
10.07
3.69
7.71
9.49
17.6
23.99
44.94
34.85
18.58
21.57
29.08
44.98
Div. Payout %
5%
0%
6%
5%
9%
10%
9%
11%
22%
19%
14%
0%
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
25
25
25
25
25
25
25
25
25
25
25
25
Reserves
2,183
2,234
2,430
2,663
3,097
3,602
4,676
5,467
5,817
6,307
6,923
8,038
Borrowings
935
867
716
628
465
501
265
807
1,481
1,438
1,363
809
Other Liabilities
669
765
788
799
961
1,130
1,099
1,338
1,300
3,326
3,432
3,477
Total Liabilities
3,812
3,892
3,960
4,116
4,549
5,258
6,066
7,637
8,623
11,097
11,744
12,350
Fixed Assets
1,800
2,014
1,983
1,953
1,940
2,059
2,072
2,418
2,751
4,554
4,267
4,627
CWIP
267
129
95
73
66
133
235
306
140
343
622
773
Investments
16
26
136
87
120
310
505
989
626
862
980
844
Other Assets
1,729
1,723
1,746
2,003
2,422
2,756
3,254
3,924
5,105
5,339
5,875
6,106
Total Assets
3,812
3,892
3,960
4,116
4,549
5,258
6,066
7,637
8,623
11,097
11,744
12,350
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
468
709
282
341
501
570
1,090
856
806
945
1,321
1,142
Investing
-689
-218
-149
-135
-165
-509
-521
-851
-725
-1,215
-870
-247
Financing
251
-462
-159
-130
-183
-137
-306
427
507
-553
-283
-754
Net Cash Flow
29
29
-26
75
153
-76
264
432
588
-823
169
142
Free Cash Flow
-207
463
147
206
322
277
731
380
347
543
551
486
CFO/OP
100
251
74
88
88
80
86
80
110
94
97
78
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
41
57
58
67
66
71
55
57
58
80
77
77
Inventory Days
293
289
290
286
316
294
337
337
276
350
336
353
Days Payable
97
145
130
137
154
135
140
101
83
110
111
122
Cash Conversion Cycle
237
200
218
216
228
229
251
293
251
321
302
308
Working Capital Days
68
61
74
80
88
88
103
102
71
111
101
109
ROCE %
14%
5%
9%
10%
16%
19%
31%
20%
11%
13%
15%
17%

Shareholding Pattern

As of Jun 2026
Promoters 44.72%
DIIs 37.04%
FIIs 10.72%
Public 7.19%
Government 0.32%
Total 99.99%
  Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
46.29%
46.29%
46.30%
46.30%
46.30%
44.72%
44.72%
44.72%
44.72%
44.72%
44.72%
44.72%
FIIs
9.86%
10.27%
10.51%
10.85%
10.83%
11.06%
10.75%
10.67%
10.42%
10.62%
10.63%
10.72%
DIIs
34.72%
34.19%
34.05%
33.46%
33.90%
35.36%
35.73%
35.88%
36.45%
36.99%
37.13%
37.04%
Government
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
0.32%
Public
8.80%
8.93%
8.82%
9.07%
8.64%
8.53%
8.45%
8.41%
8.09%
7.33%
7.21%
7.19%
No. of Shareholders
95,930
82,809
81,165
84,753
82,975
90,189
88,306
85,582
82,870
77,673
82,184
82,060

Documents

Frequently Asked Questions about Ipca Laboratories Ltd

What does Ipca Laboratories Ltd do?
Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)
Where is Ipca Laboratories Ltd (IPCALAB) listed?
Ipca Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: IPCALAB and BSE: 524494. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Ipca Laboratories Ltd belong to?
Ipca Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of Ipca Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Ipca Laboratories Ltd is 39.94. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Ipca Laboratories Ltd?
Over the past 52 weeks, Ipca Laboratories Ltd has traded between a low of ₹1,251.6 and a high of ₹1,944.9. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Ipca Laboratories Ltd?
Ipca Laboratories Ltd has a Return on Equity (ROE) of 12.51%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Ipca Laboratories Ltd on Tapetide?
On Tapetide, you can view Ipca Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Ipca Laboratories is engaged in the manufacturing and marketing of pharmaceuticals.(Source : 201903 Annual Report Page No: 68)

Website ipca.com
CEO Mr. Premchand Godha A.C. A., B. Com., CA
Employees 16,778
Listed 1995-02-01
Face Value ₹ 1
Issued Size 25,37,04,218

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List